Deutsche Bank Maintains Buy Rating On ANAC

Anacor Pharmaceuticals, Inc. ANAC “is an emerging pharmaceutical company developing new drugs based on boron chemistry, an area that has largely been neglected by industry to date,” Deutsche Bank reports. “Anacor has developed expertise in identifying and synthesizing boron-based compounds,” Deutsche Bank writes. “By modulating boron's reactivity to optimize interaction with biological targets, the company has developed several compounds with disease-specific selectivity. Given a promising product pipeline emanating from this technology, combined with an attractive valuation, we rate the shares Buy.” Anacor Pharmaceuticals closed Wednesday at $6.94.